** Shares of Orthocell Ltd OCC.AX rise 3.8% to A$1.52, their highest since April 10
** The biotech firm receives regulatory approval from Health Canada to commence sales of its flagship nerve repair product Remplir in Canadian market
** Co says first sales expected in the second half of 2025
** Stock up 11.1% YTD, including moves in the current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.